DR. LESLIE WILLIAM HUSON MEDICAL STATISTICIAN
______
OVERVIEW
32 years’ experience of statistical design and analysis of clinical trials (Phase I, II, III, IV) with multinational pharmaceutical company, CRO, and as freelance consultant/contractor. Responsible for statistical work on several successful US and European marketing approvals; substantial experience of liaison with regulatory authorities. Active in statistical research and teaching.
______
EDUCATION
PhD Biostatistics Imperial College (1985)
Diploma in Statistics (Distinction in Medical Statistics) Institute of Statisticians (1978)
B.A. (Hons) Biology University of York (1974)
______
CAREER
October 1995 – January 2009, January 2010 - Present
FREELANCE CONSULTANT MEDICAL STATISTICIAN
Working with pharmaceutical and biotechnology client companies on design, statistical analysis and reporting of clinical trials. Also teaching and researching various statistical aspects of clinical trial design and analysis, especially in relation to Bayesian Statistics, Simulation and related techniques, and Adaptive Clinical Trials.
February 2009 –December 2009
Director/Global Head of Biostatistics, Cmed Clinical Research Services Limited
March 1985-September 1995
Head of Statistics Section - Wellcome Foundation Limited
March 1977-February 1985
Consultant Statistician - Civil Service Science Group
______
ACADEMIC ACTIVITIES
Honorary Lecturer in Medical Statistics, Imperial College London
______
SELECTED PUBLICATIONS (FULL LIST AVAILABLE ON REQUEST)
______
Prague JK, Roberts RE, Comninos AN, Clarke S, Jayasena CN, Nash Z, Doyle C, Papadopoulou DA, SR, Mohideen P, Panay N, Hunter MS, Veldhuis JD, Webber LC, HUSON L, Dhillo WS (2017) Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo controlled trial. Lancet (in press).
Iyasere OU,Brown EA,Johansson L, HUSON L, Smee J, Maxwell AP, Farrington K, Davenport A (2016) Quality of Life in Older patients on Dialysis: a comparison of assisted peritoneal dialysis with haemodialysis. Clinical Journal of The American Society of Nephrology 11(3):423-30.
Rizzuto I, Stavraka C, Chatterjee J, Borley J, Glass-Hopkins T, Hani Gabra H, Ghaem-Maghami S, HUSON L, Blagden S (2014) Risk of Ovarian Cancer Relapse (ROVAR) Score: A prognostic algorithm to predict relapse following treatment for advanced ovarian cancer. Int. J. Gynecological Cancer (25):416-422.
Libri V, Yandim C, AthanasopoulosS, Loyse N, Natisvili T, Law PP, Chan JP, Mohammad T, Mauri M, Tam KT, Leiper J, Piper S, Ramesh A, Parkinson MH, HUSON L, Giunti P, Festenstein R (2014) Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich’s ataxia: an exploratory, open-label, dose-escalation study. Lancet 384(9942):504-513.
Libri V,Gibbs JSR, Pinato DJ, Iddamalgoda T, Khengar RH, Gin-Sing W, HUSON L, Anand P (2014) Capsaicin 8% patCH for Treprostinil SC infusion site pain in Pulmonary Hypertension Patients. Br Journal of Anaesthesia 112 (2): 337–47.
Barnes GD, Alam S, Carter G, Pedersen CM, Lee KM, Hubbard TJ,Veitch S, Jeong H, White A, Cruden NL, HUSON L, Japp AG, Newby DE (2013) Sustained Cardiovascular Actions of APJ Agonism During Renin-Angiotensin System Activation and in Patients with Heart Failure. Circulation: Heart Failure: 6:482-491.
Rhodes CJ,Wharton J, Boon RA, Roexe T, Tsang H, Wojciak-Stothard A,Chakrabarti A,Howard LS,Gibbs S, Lawrie A, Condliffe R,Elliot CA, Kiely DG, HUSON L, Ghofrani HA, Tiede H, Schermuly R, Zeiher AM, Dimmeler A,Wilkins MR (2013). Reduced miR-150 is associated with poor survival in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine 87(3):294-302.
HUSON LW (2012) Phase I Oncology Trials Incorporating Patient Choice of Dose. British Journal of Cancer 107: 1022-1024.
HUSON LW, Kinnersley, N (2009) Bayesian Fitting of a Logistic Dose-Response Curve with Numerically-Derived Priors. Pharmaceutical Statistics 8(4): 279–286.
Wortham NC, Ahamed E , Nicol SM, Thomas RS, Periyasamy M, Jiang J, Ochocka AM,Shousha S, HUSON L, Bray SE , Coombes RC, Ali S, Fuller-Pace FV. (2009) The DEAD box protein p72 regulates ERα-/Estrogen-dependent transcription and cell growth, and is associated with improved survival in ERα positive breast cancer. Oncogene 28(46):4053-4064.
HUSON LW, Chung J, Salgo M. (2007) Missing Data Imputation in Two Phase III Trials Treating HIV Infection. Journal of Biopharmaceutical Statistics 17: 159-172.
HUSON LW, Chung J, Salgo M. (2006) Multiple Polyexponentials and Quasipolynomials as Empirical Nonlinear Regression Models: a case study with HIV viral load data. Journal of Biopharmaceutical Statistics 16: 165-179.
Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink H-J, Delfraissy J-F, Lange J, HUSON L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M. (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV1 in Europe and Australia. New England Journal of Medicine 348 (22):2186-2195.
Welliver R, Monto S, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson H, HUSON L, Ward P, Oxford J (2001) Effectiveness of Oseltamivir in Preventing Influenza in Household Contacts. Journal of the American Medical Association 285(6): 748-754.
Hayden F, Atmar R, Schilling M, Johnson C, Poretz D, Paar D, HUSON L, Ward P, Mills R (1999) Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. New England Journal of Medicine 341(18):1336-1343.
______